Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with substantial heterogeneity in clinical presentation with an urgent need for better stratification tools for clinical development and care. In this study we used a crowdsourcing approach to address the problem of ALS patient stratification. The DREAM Prize4Life ALS Stratification Challenge was a crowdsourcing initiative using data from >10,000 patients from completed ALS clinical trials and 1479 patients from community-based patient registers. Challenge participants used machine learning and clustering techniques to predict ALS progression and survival. By developing new approaches, the best performing teams were able to predict disease outcomes better than currently available methods. At the same time, the integration of clustering components across methods led to the emergence of distinct consensus clusters, separating patients into four consistent groups, each with its unique predictors for classification. This analysis reveals for the first time the potential of a crowdsourcing approach to uncover covert patient sub-populations, and to accelerate disease understanding and therapeutic development.
Building upon the success of the earlier prediction challenge, the 2015 DREAM ALS Stratification Prize4Life Challenge (The ALS Stratification Challenge) was a crowdsourcing initiative that sought to extend the scope of prediction algorithms by inviting participants to stratify the ALS patient population into distinct clusters and develop separate predictive models for each subpopulation. The ALS Stratification Challenge included both disease progression and survival as predicted outcome measures and using either clinical trial or community registries data. This was designed to increase the relevance and applicability of predictive models to a broader patient population, to flush out any differences between the general patient population and the clinical trial population and to uncover clinical markers with high predictive value which are not collected as part of current routine clinical practice. Thus, the challenge was divided into four sub-challenges in which participants predicted either disease progression or survival while using data from either PRO-ACT or ALS registries. A prize of $28,000, collected through a crowdfunding effort, was divided equally between best performers of the four sub-challenges.
In this publication we describe the results of the challenge including analysis of the best performing algorithms' performance and methods as well as findings regarding patient sub-populations and relative importance of different predictive features obtained from cross-model assessment.
Results

Challenge design
The ALS Stratification Challenge was developed and ran through a collaboration between the nonprofit organizations Dialogue for Reverse Engineering Assessments and Methods initiative (DREAM, http://dreamchallenges.org/) and Prize4Life (www.prize4life.org.il) using the Sage Bionetworks Synapse platform (www.synapse.org). The challenge was based on two datasets: (1) ALS clinical trials data collected through the PRO-ACT database, and (2) community-based ALS clinical data collected through ALS registries. Both datasets contained longitudinally sampled demographic and clinical information with some additional genetic (specific mutation) and family history data in the registries and detailed laboratory tests in PRO-ACT (See Supplementary material part 1 and 2 for detailed description of both datasets and the challenge description as given to participants, respectively).
The challenge was divided into four sub-challenges: (1) Predicting disease progression or (2) survival probability using PRO-ACT data and (3) predicting disease progression or (4) survival probability using ALS registries data. Challenge participants were asked to use patients' data from the first 3 months of records to predict disease progression at 12 months or probability of survival at 12, 18 & 24 months. Disease progression was defined as the slope of the ALS Functional Rating Scale (ALSFRS or ALSFRS-R) between 3 and 12 months (see online methods). The challenge ran between June and October 2015 and drew 288 registrants, eventually leading to final submissions by 30 teams (88 individual participants) from 15 countries (see Supplementary material part 3 for participant survey).
Approach to performance assessment
To avoid overfitting of algorithms 19 , two datasets were used for each sub-challenge, a training dataset accessible to participants in full, and a validation set, which was only available to the challenge organizers and was used to evaluate the prediction accuracy of submitted algorithms at the end of the challenge. For the PRO-ACT sub-challenges, data from the publicly available PRO-ACT database was used as the training set, and a separate set of data from six additional clinical trials which were not previously publicly available, was used for validation. The registry data, which was never before made publicly available, was divided randomly (split evenly across the two registries) into training and validation sets.
The accuracy of disease progression predictions was assessed by the combination of three different metrics: concordance index (CI), Pearson's correlation coefficient (PCC) and root mean squared deviation (RMSD). The evaluation of survival prediction accuracy was based on the CI scores for the three survival probability predictions (probability of survival at 12, 18 & 24 months) and confirmed by a time-ROC analysis. The three scores for each sub-challenge were transformed into z-scores that were then combined to obtain a ranking of the submitted algorithms (see online methods). Performance was also compared to two baseline algorithms which were based on the top performing prediction algorithms submitted to the 2012 ALS prediction challenge 16 , adapted to the requirements of the new challenge (see Supplementary material part 4).
Clustering patients into subgroups was not mandated, but participants were encouraged to use clustering to enhance performance. The challenge introduced an additional requirement that predictions are to be made based on a limited number of clinical features. The requirement for limiting the number of features was highlighted by our clinical advisors to facilitate the application of predictive algorithms in natural clinical setting 13 . A preliminary analysis indicated the benefit from clustering (in terms of improved prediction accuracy) tends to increase when the number of features is restricted, and this effect plateaued at around 6 features (see Supplementary material part 4). Thus, participants were asked to write algorithms that first selected the most informative features (up to 6 features), and in a second step used only the data from these selected features to make progression or survival predictions ( Figure 1 ). To enforce the separation between these two steps as well as to completely hide the validation set we required participants to implement their algorithms in Docker containers (https://docs.docker.com/) executed on the IBM Z cloud (https://www.ibm.com/it-infrastructure/z/capabilities/enterprise-security). This way, we could run the algorithms in a secured environment where the participants could not see the validation data or other jobs running. data, and first (1) applied various data pre-processing methods, such as data imputation, aggregation, quantization and more. Next, (2) algorithms could cluster the patient population into any number of sub-groups and (3) select the most informative features for each cluster (up to a maximum of 6 features). Then (4) a "predictor" component had to use values of the selected features to predict either disease progression or survival for any given patient. In the scoring of the challenge, the algorithms made predictions for patients that were not part of the original datasets available for algorithms training, and the accuracy of these predictions was assessed.
Comparative assessment of prediction methods
In general, the top performing teams in each sub-challenge (except for the registry progression sub-challenge) significantly outperformed the best baseline algorithm ( Figure 2 , See Supplementary material part 5 for full results). Random forest was by far the most commonly used prediction method, with overall very good results. It was the method used by the best performing team in the registry progression sub-challenge and by most algorithms ranked between the 2nd and 8th places across all four sub-challenges ( Figure 2a ). Another successful method included a Gaussian process regression model with an arithmetic mean kernel, which was the best performing for the two survival challenges but did not perform so well for the progression challenges. The performance of the top teams, as was observed in other crowdsourcing challenges 20, 21 , varied substantially even if the same machine learning method was used, and depended to a large extend on data pre-processing, especially feature selection and representation of time-resolved features.
Here, the best performing teams followed the successful logic of the previous ALS prediction prize 16 , where time-resolved information was represented by a combination of simple summary statistics (for instance minimum, maximum and average of the feature values). Due to the restriction of 6 features used for the prediction of a patient's outcome, teams also needed to devise a suitable feature selection strategy. This was achieved by evaluating the contribution of the complete set of selected features (as opposed to selecting them one by one), for example through Gaussian regression models. This defined the outcome variable more precisely, which led to a more adequate training of regression models (here: Gaussian process models) explaining the algorithm's superior prediction performance. In line with these results, the strategy outperformed a standard Cox model by 20% accuracy 22 .
Notably, for the sub-challenges running on the PRO-ACT database, the best performing algorithms significantly outperformed the winning method from the first challenge 16 . This is even more noteworthy given that the validation set was not randomly divided from the training set, but actually included the more difficult and realistic criteria of application of the algorithms to a data comprising of six new never used before trials.
Predictive clinical features
The challenge's requirement of using only up to six features for prediction encouraged participants to identify the most informative features for the prediction of disease progression or survival. We assessed the number of times each feature was used for prediction across all submitted algorithms and identified the features most frequently used within and across the different sub-challenges ( Figure 3 ). Features that are recommended to be assessed by clinicians more often to aid prognosis are marked in bold.
The most frequently used features for all sub-challenges were those that are well described in the literature as being strongly related to ALS prognosis: time from disease onset and total ALSFRS score 23, 24, 25 . Age and gender were also frequently used but were more informative for predicting survival rather than disease progression, in line with literature 22, 23, 24, 26, 27, 28 . While age and gender were generally predictive in this data as well, they were not specifically more predictive for one particular subgroup of patients, and therefore less relevant for stratification, while still not deterring from its overall importance as a predictor. Bulbar function is also known to be particularly informative for clinical outcome prediction 24, 25, 26 and ALSFRS questions 1 and 3 (bulbar functions) were selected more frequently compared to any other functional domains across all sub-challenges. Interestingly, ALSFRS question Q2 (salivation) was rarely used, in line with previous works indicating this question might be less well correlated with total ALSFRS scores and/or disease progression, due to effective available treatment options 29 .
Data availability was another important factor for feature selection. For example, while weight or BMI, is known to correlate with ALS prognosis 30, 31 and was frequently selected for predictions for the PRO-ACT dataset, it was recorded in only <10% of the cases in the registry data, making it unusable for predictions ( Fig. 3 ). The potential predictive benefit of features not routinely collected in clinical practice was also observed with respect to features evaluating breathing capacity. Given that loss of breathing function is the main cause of death for ALS patients 32 , it is not surprising that breathing-related features, primarily Forced Vital Capacity (FVC) were commonly used for predictions in both PRO-ACT sub-challenges. However, in the registry data, where FVC data was not available and breathing was only assessed by the ALSFRS scale breathing-related questions were less frequently used for prediction. This suggests that clinicians could potentially gain better insight into individual patient prognosis by incorporating a few rather accessible measures into routine clinical monitoring. Features whose recording can result in better predictability are shown in bold in Figure 3 . Indeed, since the challenge ran, clinics involved in the Italian registry used in this challenge have been careful to add measurements of patient weight, BMI and respiratory functions.
Clinically relevant patient clusters
In this challenge we used a crowdsourcing approach to explore different stratification schemes for ALS patients and use them to identify clinically significant patient sub-populations. Such subpopulations can be of great value for understanding the ALS pathology, improving clinical care and planning better, more efficient clinical trials. We were also hoping to learn whether clustering could help improve the performance of prediction algorithms, especially when applied to heterogeneous patient populations (i.e., registry data) when the number of available clinical features is limited.
Most challenge participants chose not to incorporate a clustering component in their prediction algorithm, and overall, we did not observe any consistent advantage (in terms of improved prediction accuracy) for clustering in any of the evaluation metrics. The main goal of clustering, however, was not necessarily to impact prediction accuracy, but to reveal, across a large variety of methods, consistent clusters of patients that could uncover clinically significant ALS patient subpopulations. This sort of analysis can only be accomplished in the context of a large communal effort that allows comparison of independently generated algorithms working on sufficiently large datasets, as was the case in this challenge. To identify consistent clusters, we assigned patient pairs with scores reflecting how often they appear together in the same cluster across all different algorithms and used the resulting connectivity matrix as input to correlation-based k-means analysis (see online methods and Supplementary material part 6). The resulting clusters reflected groups of patients that consistently and significantly tend to be clustered together across different clustering schemes and algorithms. The different clustering methods led to substantially different results, for instance, in the registry progression and survival subchallenges the numbers of clusters varied from 2 to 131 and from 2 to 159, respectively. An important result of this analysis was that the patients of each of the four sub-challenges could be easily clustered into in a consistent small set (3-4) of visually discrete consensus clusters ( Figure   4 ). In both sub-challenges based on PRO-ACT, patients within consensus clusters were significantly more strongly connected than expected by chance (pairs of patients co-clustered significantly with FDR<5% are depicted as edges in Figure 4b ). The stronger clustering effect in the PRO-ACT vs. the registry sub-challenges is likely a reflection of sample size (10,000+ vs.
~1,500 patients, respectively).
Overall, consensus clusters could be broadly regarded as classifying patients as slow progressing ("red"), fast progressing ("blue"), early stage ("purple") or late stage ("green"). We chose to focus on clinical characteristics of the PRO-ACT progression sub-challenge, since these consensus clusters reached the highest level of statistical significance, but similar clusters were found across all sub-challenges.
One cluster, the "red" or "slow progressing" cluster included patients who, despite having experienced symptoms for a relatively long time (2.2 years from disease onset, on average) still maintained relatively high functional capabilities (average ALSFRS-R scores of 40.25 at the beginning of the clinical observation period), with functional impairments mostly limited to limbs (either legs or arms) and little bulbar or respiratory involvement. Accordingly, these patients had slow disease progression (annual average loss of -0.48 on the ALSFRS-R scale). These are the patients with the best prognosis for ALS and therefore noteworthy to assess closely as they might aid clinicians in predicting favorable disease progression. First, only few (3%) of these "slow progressing" patients had bulbar onset. While bulbar onset had been frequently correlated with poorer prognosis [22] [23] [24] , this cluster analysis suggests that bulbar patients will rarely be classified as a slow progressing disease presentation. A second important observation is low creatinine levels (average of 67 mcmol/L in the first three month of data collection, compared to a normal desired range of 74.3-107mcmol/L). Creatinine was reported in the previous challenge 16 , as a predictor of disease progression and these results suggest that it might also serve as a predictor of this special case of patients with improved prognosis.
A very similar cluster was observed in the analysis of clusters derived from the PRO-ACT survival sub-challenge, with patients living with ALS for an average of 1.5 years while displaying little functional decline (average total ALSFRS_R score 39.4), largely intact breathing functionality (FVC 94.4% of normal on average) and an ALSFRS progression rate of -0.72points/months.
To characterize clusters and the involved patients for clinical relevance, we compared all pairs of clusters (using ANOVA and t-test, resulting in multiple-testing corrected false discovery rates or FDRs) to assess which features had values specifically different between the clusters (Figure 4c ).
We also examined the correlation between feature values and clinical outcome (progression rate)
in each cluster to identify features which were important for prediction in some clusters but not in others. Based on the clusters clinical features analysis, the two features unique for this "slow progressing" cluster were urine creatinine and segmented neutrophils (Figure 4b-c ). Both of these features are therefore potential biomarkers of slow progression in ALS. Neutrophils were indeed found to be connected to ALS progression in some studies 33, 34 but not others 35 and the stratification to sub-groups might shed further light on these results.
Another cluster that was superficially similar but in fact quite different was the "purple" or "early stage patients". In our pair-wise comparison of features across clusters, the "early stage" and "slow progression" clusters ("purple" and "red" clusters respectively) were similar in having high ALSFRS and FVC scores in the first 3 months of assessment, indicating little functional impairment (Figure 4b-c) . However, the distinctive feature of patients in the "purple" cluster was the fact that they were early in their disease, on average ~10 months from symptom onset. Thus, the largely preserved functional state of this patients could be attributed to their early disease stage, rather than a slow progression rate. Indeed, with time these patients became fast progressors (-0.93 Importantly, a similar yet more severe cluster was observed in the PRO-ACT survival data, with patients showing diminished disease states (initial ALSFRS-R of 24 ALSFRS points) and survival (average of 443 days from trial onset). When clustering for survival, it was noticeable that women are more likely to be fast progressors (53% women compared to 40% in the general patient population), even beyond their higher likelihood to have bulbar onset (32% of women). This cluster of patients with the poorest prognosis was also found in the registry consensus clustering for both the progression and the survival data, with short survival times, fast progression and high rate of bulbar onset patients.
ALSAFRS
There were also features that stood in our pair-wise comparison because they were significantly different between almost all pairs of clusters. Unsurprisingly the most discriminative feature was time of onset (which was significantly different between the "red", "blue" and "green" clusters).
However, equally discriminative were also ALSFRS question 1 (speech) and our combined measure mouth, averaging ALSFRS questions 1-3 (speech, swallowing and salivation), highlighting again the important role of bulbar function in discriminating ALS consensus clusters.
Discussion
Disease heterogeneity, and particularly large unexplained variance in disease progression rate and survival, is a hallmark feature of ALS disease 38 43 , made prediction more challenging and overall registry prediction algorithms achieved lower levels of prediction accuracy. We suggest a number of clinical features ( Fig. 3) , such as FVC and weight, which could be added to routine clinical assessment to potentially improve prediction accuracy and aid clinicians in predicting individual patient prognosis. Conversely, a number of features that could be found exclusively in the registries data, including common genetic mutation data and detailed onset site assessments, were both highly informative for prediction and should be considered for incorporation into ALS clinical trial screening or baseline assessment.
We examined the features most often chosen for prediction by the different challenge participants to see what features had the highest predictive power. This analysis revealed several features, already well reported in the literature, such as age, gender [22] [23] [24] and respiratory capacity. 22, 29, 44, 45, 46 which were strong predictors of survival, but were less informative for predicting disease progression, whereas other features, including limb motor function ALSFRS-R scores (hands and legs function) and specific ALS staging scores 47 were more informative for predicting disease progression rather than survival. Creatinine, already suggested before as a measure predictive of ALS prognosis 16,29,48,49 , 50 was also found to be predictive in this challenge, and interestingly this was specific for patients early in their disease. Segmented neutrophils were also suggested by our analysis as a relevant novel predictor, specifically for slower progressing patients, while SVC and ALSFRS "trunk" scores were associated with outcomes only specifically for patients later in their disease.
The main goal of this challenge was to uncover clinically meaningful subgroups of ALS patients, a challenging task since no known "gold standard" exists for ALS patient stratification. In this study we applied a "bottom-up" approach to patient stratification: we did not make any a-priory assumptions regarding patient sub-populations, but instead defined patient clusters by a "consensus vote" based on participants' submitted algorithms. Challenge participants were free to base their clustering on any subset of the available clinical data, choose any type of clustering method and any number of clusters. While clustering was not directly related to any immediate benefit in algorithms' prediction accuracy, it did reveal consistent patterns of patient classification that are of great potential interest. We suggest that these clusters could be used to identify Overall, these results suggest a novel stratification scheme for ALS, with relevant classifiers and group-specific predictors, and it would be highly interesting to further prospectively assess its benefit for clinical care and clinical trials. As most clinical trials enroll patients with high functions, they might over-represent patients from the "early" patient" and "slow progressing" cluster and under-represent the other two cluster of patients. It would also be interesting to assess whether the predictors revealed here can uncover new insights about disease mechanisms.
To summarize, the ALS Stratification Challenge and subsequent analysis provided us with algorithmic tools and insights about stratifying ALS patients and uncovered meaningful subgroups of patients. Patient stratification is always a challenge, and even more so for rare diseases with substantial heterogeneity where effective stratification can advance clinical development substantially. Stratification is also highly needed for clinical care, to allow more personalized treatment. The tools and insights presented in this study can offer a first attempt for improvement in clinical trial development, selection and interpretation, accelerating the development of a muchneeded treatment for a dire aliment such as ALS.
Supplementary information
We provide additional method description and results (ALS Stratification Supplement.pdf), the solver-provided descriptions of submitted algorithms (Challenge writeups.pdf) as well as data on solver predictions, the cluster analysis and assessment scripts (stratification.zip, see readme files contained there for details).
Online Methods:
Datasets
The challenge made use of two datasets: data collected during clinical trials (PRO-ACT) and data collected during routine visits to ALS clinics (ALS registries). Both datasets included both static and time resolved measurements covering a wide range of data types and clinical measurements (full data dictionaries for both datasets can be found in the supplementary material). The time in which measurements were taken was noted in days relative to clinical trial onset or to first clinic Briefly, ALSFRS was calculated as:
Where t1 and t2 were the time points at the first and last clinic records in the relevant time period 92-365 days in which total ALSFRS scores were recorded. Whereas time data in the both challenge datasets was given in days, it was converted to months for the calculation of ALSFRS slope, according to the following: t(months)= (t(days)/365) *12). Patients had to have at least two clinical records in the relevant time period for their data to be used for validation (see Table 2 ). Participants were required to write algorithms that would predict ALSFRS slope between 3 and 12 months, based on data collected in the first three months of clinical records. Patients whose final records were on or before day 90 (from onset of clinical trial or of clinical records) were excluded from the survival analysis (see Table 2 ). Challenge participants were required to write algorithms that predicted the likelihood of survival for each patient at three time points; 12, 18 and 24 months from the onset of clinical records.
Predictions assessment and scoring scheme
All methods for performance assessment were based on evaluating how close the algorithms'
predictions were compared to the gold standards, averaged across all patients. We used three different evaluation metrics to assess submitted algorithms' performance in the disease progression sub-challenges. Two methods, the root mean square deviation (RMSD) and Pearson's correlation (PCC) were used and described in the previous ALS prediction challenge (Kueffner et al., 2015) .
In the current challenge we added a third evaluation metric: the concordance index (CI), which evaluates the similarity of ranks between predicted and actual ordered lists of measurements. The concordance index was the only metric used to evaluate performance in the survival prediction sub-challenge, since it is commonly used in survival analysis and is best suited for assessing censored data [Noren et al., 2016] . When there is no censored data or ties, the c-index between a predicted list of survival times of patients, = { + , ( , … , 7 }, and the actual survival times for the same patients, = { + , ( , … , 7 }, is calculated as:
Please see supplementary data on details accommodating for the possibilities of ties and censored data.
The three performance assessment (or three CI values, in the case of survival prediction) were combined using Z-score transformation. We generated 100,000 random sets of predictions for each of the four sub-challenges, by randomply assigning "gold standard" progression or survival values to patients. We then calculated the RMSD, PCC and CI scores for each of these random shuffles, and used the resulting three sets of 100,000 values to calculate the mean and standard deviation (SD) of each of the three scoring metrics. These mean and SD values were used to calculate the Zscores for the three assessment metrics for each of the submitted algorithms, given by: 
Consensus clusters and determination of discriminating features
For each subchallenge, we integrated the teams' clusterings into a consensus clustering. First, we created a square patient x patient co-clustering matrix M where each matrix element mi,j contained a normalized score that expressed how often the corresponding patients i and j appear together in a single cluster across all team submissions. The normalized score takes the size of the teams' clusters into account such that two patients clustered together in a smaller cluster receive a larger weight. The scores mi,j were calculated as the sum of contributions (eq. 1), across all submissions s, where patients i and j appear together in the same cluster:
where p is the total number of patients in the given sub-challenge and cs is the number of patients in the cluster of submission s that includes both i and j (to normalize by cluster size).
We next determined the statistical significance of mi,j values, i.e. to determine whether patients i and j are clustered together more often than expected by chance. We randomly assigned patients into clusters of the same size as contained in the original submissions, and repeated this random sampling process 100 times. We then calculated mi,j scores for each set of randomly assigned clusters, giving us 100 mi,j scores for each i, j patient pair. We used these permuted mi,j value to calculate a false discovery rate for any given mi,j score derived from the participants' submissions data, by assigning:
where Nperm is the number of permutations , Ntrue and Nfalse refer to the number of scores computed from submitted and permuted data, respectively, that were less or equal than the given score. This approach to FDR calculation was adapted from significance analysis of microarrays Subsequently a FDR threshold of 5% was applied to identify significantly pairs of patients that significantly tend to be clustered together.
A graph of significant pairs was then plotted using the graphviz software package in order to visually determine a plausible number of clusters k. To generate the final patient clusters, we performed k-means clustering for k clusters based on the matrix M using average linkage and Pearson's correlation metric. Thus, the correlation metric calculates the distance between patients i and j by comparing the corresponding rows, denoted as mi. and mj., in the matrix M.
This analysis identified three consensus clusters for both survival and the registry progression sub-challenges and four clusters for the PROACT progression sub-challenge.
Detection of features differentially distributed across patient groups
After finding a small number of consensus clusters of patients for each sub-challenge, we determined the features that discriminate between consensus clusters by statistical tests. Values of longitudinal variables (e.g., ALSFRS) were averaged across time, and we looked at average values of two different time periods consistent with the challenge's overall design: 0-3 months and 3-12 months. We applied one-way analysis of variance (ANOVA) to continuous features (e.g. age of onset) and Fisher's exact test to discrete features (e.g. site of onset). This leads to two matrices, C and D, capturing the values of the continuous and discrete features, respectively.
Rows in these matrices correspond to the features, columns to the patients. In addition, each feature vector (containing the values for that feature across the p patients) was randomly permuted a hundred times and statistical tests were applied to the 100 randomized datasets to compute FDRs (analogous to the description above) separately for the results from Fisher's exact test and ANOVA.
We then regard the relative ranks from the ANOVA and Fisher as new test values. From these, we compute FDRs now across discrete and continuous features together. By this integrated statistical assessment we obtained FDR values for all features. Features were deemed statistically significant across all clusters if they exhibited FDR values of <5%. See below pseudo code for details.
Subsequently, t-tests were applied to identify all pairs of clusters where ANOVA determined that continuous features exhibited significantly differential values (FDR < 5%). The same permutations were applied to the feature vectors as above, such that we were able to transform ttest p-values into false discovery rates analogously. As before, we regard a feature as statistically significantly different between two clusters if such a comparison resulted in an FDR <5%. FDRs do not need multiple testing correction as it is already built into the permutation test. Note that we applied the ANOVA "trick" here: pairwise comparisons were only performed (and thus subject to multiple testing correction) for features with overall significance across all clusters.
This leads to a less severe multiple testing correction and accordingly to a more sensitive test for the pairwise comparisons in contrast to the case were pairwise comparisons would have been performed and corrected for all features.
We then transformed the pairwise comparisons for each feature into cluster specific levels l in order to create a heatmap. If a comparison between a pair of clusters (a,b) is significant, and the given feature displays higher values in a as compared to b, we applied l(a)=l(a)+1 and l(b)=l(b)- and r, respectively. The backslash notation denotes the removal of an element, i.e. in a'=a' \ max(a'), the entry with the highest value is removed from a'. Analogously, the FISHER test statistic f is calculated for the discrete features in D (pseudo code in the right panel). Finally, FDRs are calculated by comparing the relative ranks from the true statistics r vs. the relative ranks from the permuted statistics r' across discrete and continuous features (lower panel). tot = 101*size_d rank = 0 for i=1 to size_d do f i = FISHER(g, d i. ) for j=1 to 100 do d i. = shuffle(d i. ) f' i,j = FISHER(g, d i. ) end end for f i in num_sort(f) do
while max(f')>f i do rank = rank+1 push r', rank / tot f' = f' \ max(f') end rank = rank+1 push r, rank / tot end tot = 101*size_c rank = 0 for i=1 to size_c do a i = ANOVA(g, c i. ) for j=1 to 100 do c i. = shuffle(c i. ) a' i,j = ANOVA(g, c i. ) end end for a i in num_sort(a) do while max(a')>a i do rank = rank+1 push r', rank / tot a' = a' \ max(a') end rank = rank+1 push r, rank / tot end tp = fp = 0 for r i in num_sort(r) do while min(r')<r i do fp = fp+1 r' = r' \ min(r') end tp = tp+1 FDR i = fp / (tp*100) end
